EnGeneIC Limited to Present at the 34th Annual J.P. Morgan Healthcare Conference

Jan 05, 2016, 08:30 ET from EnGeneIC Limited

NEW YORK and SYDNEY, Jan. 5, 2016 /PRNewswire/ -- EnGeneIC Limited, a clinical stage biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced it will present at The 34th Annual J.P. Morgan Healthcare Conference to be held January 11-14, 2016, at the Westin St. Francis Hotel, San Francisco.

Himanshu Brahmbhatt, Ph.D., joint-CEO and director of EnGeneIC, will provide an overview of the company's business, including the latest clinical results, as well as discuss the company's groundbreaking EDV™ nanocell technology platform as a first-in-class cytoimmunotherapeutic, and its rapidly advancing development pipeline. Dr. Brahmbhatt will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.


The 34th Annual J.P. Morgan Healthcare Conference


Wednesday, January 13, 2016

Presentation Time: 

9:00-9:25 am (Pacific Time) 


Westin St. Francis San Francisco; Elizabethan D Room


A live audio webcast of the presentation will be available on EnGeneIC's website, www.engeneic.com.  The webcast will be archived and available for replay for 90 days.

About EnGeneIC and the EDV™ Nanocell Technology
EnGeneIC is an emerging biopharmaceutical company focused on developing its proprietary bacterially-derived EDV™ nanocells as a powerful nanoparticle drug, siRNA, or miRNA delivery system designed to directly target and effectively kill tumor cells with minimal toxicity, while at the same time stimulating the immune system's natural anti-tumor response. Intravenously injected EDV™ nanocells exit the leaky vascular system only found within tumors and attach to cancer cells via a specially designed, targeted bi-specific antibody. Once attached, the nanocell is able to enter the tumor cell and deliver a drug, siRNA, or miRNA payload at high concentrations, intracellularly. In doing so, EDV nanocells enable current cancer treatments to be more potent and far less toxic, while also offering a potential new means for treating drug-resistant cancers.  In parallel, the bacterial cell wall of the nanocells stimulates key components of the immune system, which are then activated to seek out and destroy cancer cells.

The EDVTM has shown promising results in early clinical studies and EnGeneIC is currently planning to undertake clinical trials in several cancer indications in Australia and USA.

For more information, please visit www.engeneic.com

For EnGeneIC:
Himanshu Brahmbhatt, Ph.D.
Joint-CEO and Director

U.S. Investor Contact:
Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D. 

U.S. Media Contact:
Tiberend Strategic Advisors, Inc. 
Amy S Wheeler

Australia Media Contact:
Felicity Moffatt

SOURCE EnGeneIC Limited